Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

Esperion (NASDAQ: ESPR) today announced that one featured presentation in the Late Breaker/Featured Science track and three poster presentations have been accepted for the AHA Scientific Sessions 2024 in Chicago, IL, November 16-18, 2024.

Featured ScienceBempedoic Acid and Limb Outcomes in Statin-Intolerant Patients with Peripheral Artery Disease: New Insights from the CLEAR Outcomes TrialFeatured Science: Vascular Outcomes in the SpotlightNovember 18, 2024, 8 - 9:15 a.m. CSTPresenter: Marc P. Bonaca, MD, MPH, FAHA, FACC

Poster PresentationsLiver Steatosis and Liver Fibrosis Predict Major Adverse Cardiovascular Events in the CLEAR Outcomes TrialPoster PresentationCVD Science Smorgasbord IIZone 3, Science & Technology HallNovember 16, 2024, 10:30 - 11:30 a.m. CSTPresenter: Diederick (Rick) Grobbee, MD, PhD, FESC

Statin Intolerance due to Muscle Symptoms Affects Management of Patients: Insights from the CLEAR Outcomes TrialModerated Digital Poster Presentation 15Lipids and Management – A Deep DiveZone 3, Science & Technology HallNovember 16, 2024, 11:50 - 11:55 a.m. CSTPresenter: Ulrich Laufs, MD, PhD

Effectiveness of Lipid-lowering Therapy with Bempedoic Acid plus Ezetimibe in a Real-world CohortModerated Digital Poster Presentation 1Clinical and Translational Studies of Lipoproteins and Lipids in Vascular DiseasesZone 1, Science & Technology HallNovember 16, 2024, 1:40 - 1:45 p.m. CSTPresenter: Evelyn Sarnes, PharmD

Esperion TherapeuticsAt Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc.

Esperion Contact Information:Investors: Alina [e-mail] [phone]

Media: Tiffany Aldrich [e-mail] [phone]